Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease

(2017) Nour K. Majbour et al.   Scientific Reports

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration

(2017) K Höglund et al.   Translational Psychiatry

CSF Levels of Heart Fatty Acid Binding Protein are Altered During Early Phases of Alzheimer's Disease

(2017) Davide Chiasserini et al.   JOURNAL OF ALZHEIMERS DISEASE

PERFORMANCE EVALUATION OF NEW ABSORBANCE-BASED ELISAS FOR MEASURING DIFFERENT ALPHA-SYNUCLEIN (A-SYN) SPECIES IN CSF AND PLASMA

(2016) Erik Stoops et al.   Alzheimers & Dementia

Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis

(2016) Lucilla Parnetti et al.   Biomarkers in Medicine

Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine

(2016) Davide Chiasserini et al.   JOURNAL OF ALZHEIMERS DISEASE

Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies

(2016) Franc Llorens et al.   JOURNAL OF NEUROLOGY

Distribution and Load of Amyloid-β Pathology in Parkinson Disease and Dementia with Lewy Bodies

(2016) Dagmar H. Hepp et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression

(2016) Nour K. Majbour et al.   MOVEMENT DISORDERS

Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases

(2016) Stephen N. Gomperts et al.   JAMA Neurology

Amyloid PET Imaging in Lewy Body Disorders

(2015) Paul Donaghy et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes

(2015) N K Magdalinou et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study

(2015) Niels Kruse et al.   NEUROBIOLOGY OF AGING

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease

(2015) David C. Bäckström et al.   JAMA Neurology

Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis

(2015) Hanne Struyfs et al.   Frontiers in Neurology

Increased CSF α-synuclein levels in Alzheimer's disease: Correlation with tau levels

(2014) Sylvie Slaets et al.   Alzheimers & Dementia

Phosphorylated Tau-Aβ 42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer’s Disease in Multiplex Immunoassay Panels of Cerebrospinal Fluid

(2014) Oscar Harari et al.   BIOLOGICAL PSYCHIATRY

FABP3 Protein Promotes α-Synuclein Oligomerization Associated with 1-Methyl-1,2,3,6-tetrahydropiridine-induced Neurotoxicity

(2014) Norifumi Shioda et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature

(2014) Wei Tang et al.   JOURNAL OF NEURAL TRANSMISSION

Tau protein, beta-amyloid1–42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia

(2014) Hana Přikrylová Vranová et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease

(2014) Lucilla Parnetti et al.   MOVEMENT DISORDERS

CSF A 42 predicts early-onset dementia in Parkinson disease

(2014) G. Alves et al.   NEUROLOGY

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease

(2014) Oskar Hansson et al.   Alzheimers Research & Therapy

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease

(2014) Lucilla Parnetti et al.   Frontiers in Aging Neuroscience

CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer’s disease

(2013) Liang-Hao Guo et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration

(2013) Rahul S Desikan et al.   Molecular Neurodegeneration

Cerebrospinal fluid biomarkers in Parkinson disease

(2013) Lucilla Parnetti et al.   Nature Reviews Neurology

The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies – A systematic review and meta-analysis

(2013) Xuxin Lim et al.   PARKINSONISM & RELATED DISORDERS

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases

(2012) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders

(2011) Mathias Jucker et al.   ANNALS OF NEUROLOGY

Interaction between pathogenic proteins in neurodegenerative disorders

(2011) Kurt A. Jellinger   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

(2011) Brit Mollenhauer et al.   LANCET NEUROLOGY

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias

(2011) Lucilla Parnetti et al.   MOVEMENT DISORDERS

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

(2011) N. S. M. Schoonenboom et al.   NEUROLOGY

The Epidemiology of Dementia Associated with Parkinson's Disease

(2010) Dag Aarsland et al.   BRAIN PATHOLOGY

Heart-Type Fatty Acid Binding Protein Regulates Dopamine D2 Receptor Function in Mouse Brain

(2010) N. Shioda et al.   JOURNAL OF NEUROSCIENCE

From model system to clinical medicine: pathophysiologic links of common proteinopathies

(2010) Pamela J McMillan et al.   Alzheimers Research & Therapy

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

(2009) Yaroslau Compta et al.   MOVEMENT DISORDERS

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

(2009) Karen Koopman et al.   NEUROCHEMISTRY INTERNATIONAL

A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking

(2009) C. E. Teunissen et al.   NEUROLOGY

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

(2008) Annika Öhrfelt et al.   NEUROSCIENCE LETTERS